Jerome D. Jabbour - Apr 30, 2025 Form 4 Insider Report for Matinas BioPharma Holdings, Inc. (MTNB)

Signature
/s/ Keith A. Kucinski, attorney-in fact for Jerome D. Jabbour
Stock symbol
MTNB
Transactions as of
Apr 30, 2025
Transactions value $
$0
Form type
4
Date filed
5/2/2025, 05:19 PM
Previous filing
Dec 15, 2023

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Jabbour Jerome D President and CEO, Director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH SUITE 302, BEDMINSTER /s/ Keith A. Kucinski, attorney-in fact for Jerome D. Jabbour 2025-05-02 0001698838

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MTNB Stock Option (right to Buy) Award $0 +70.1K $0.00 70.1K Apr 30, 2025 Common Stock 70.1K $0.59 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. The options vest, subject to stockholder approval of the 2025 Plan, as to 25% of the shares on April 30, 2026 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing April 30, 2026.